Skip to main content

Table 1 Clinically significant medication-related risks that were assessed as outcomes in this study

From: Enhanced coordination of care to reduce medication risks in older home care clients in primary care: a randomized controlled trial

OutcomeAspects assessed
Number of all medicationsThe total number of regular and pro re nata (when required) medications that have been prescribed (i.e. prescribed medication that is scheduled), over-the-counter and herbal products are not included
Use of harmful medicationsIncluded Beers Criteria medications [23], psychotropic medications and anticholinergic medications according to Puustinen et al. 2012 [26].
Use of Beers Criteria [23] medicationsPotentially inappropriate medicines for older adults according to Beers Criteria [23].
Use of CNS medicationsOpioids (ATC code N01AH, N02A, N02BE51, R05DA, R05FA); anticholinergic drugs according to Puustinen et al. 2012 [26], antiepileptics (ATC code N03A); BZDs and related drugs (ATC codes N05BA, N05CD, N03AE01, N05CF, A03CA, C01DA70, M05AA51, N06CA01, N02BA71); antidepressants (ATC codes N06A, N06CA); antipsychotics (ATC codes N05A, N06CA01).
Use of Psychotropic medications
Proportion of study participants using > 3 psychotropic medications, n (%)
BZDs and related drugs (ATC codes N05BA, N05CD, N03AE01, N05CF, A03CA, C01DA70, M05AA51, N06CA01, N02BA71); antidepressants (ATC codes N06A, N06CA); antipsychotics (ATC codes N05A, N06CA01) [26]
Proportion of study participants using > 2 serotonergic medications, n (%)Serotonergic medications according to Salko database [27].
Proportion of study participants using anticholinergic medications, n (%)Anticholinergic medicines according to Puustinen et al. 2012 [26].
Proportion of study participants using antipsychotics, n (%)ATC codes N05A, N06CA01
BZD users, n (%)BZDs and related drugs (ATC codes N05BA, N05CD, N03AE01, N05CF, A03CA, C01DA70, M05AA51, N06CA01, N02BA71) [26]
Opioid users, n (%)ATC codes N01AH, N02A, N02BE51, R05DA, R05FA
PPI user, n (%)ATC A02BC
Prevalence of clinically significant drug-drug interactions (SFINX class D) [24]Interactions that should be avoided or used with caution [24].
  1. CNS central nervous system, ATC The Anatomical Therapeutic Chemical classification system, WHO 2018 [28], BZD benzodiazepine, PPI proton-pump inhibitor
\